Efficacy of Radiofrequency Micro Needling for the Treatment of Melasma in Skin of Color.

Launched by THE CLEVELAND CLINIC · Sep 26, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called radiofrequency microneedling (RFMN) to see how well it works for people with melasma, a condition that causes dark patches on the skin, particularly in individuals with skin types IV to VI. The researchers believe that RFMN could be an effective way to help reduce the appearance of melasma in patients with skin of color. The study is currently active but not recruiting new participants.

To be eligible for this trial, participants need to be at least 18 years old and have been diagnosed with melasma. They should not have used certain skin products, like retinol or vitamin C, for six weeks before the first visit, but sunscreen is allowed. Women who are pregnant or planning to become pregnant during the study, as well as anyone currently using treatments for melasma, cannot participate. Participants can expect to learn more about their condition and receive treatment, while also contributing to research that could help others with similar skin types.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males or females, at least 18 years of age
• • Fitzpatrick skin types IV-VI
• • Clinically diagnosed melasma
• • No topicals (retinol, vitamin C serum, etc) for 6 weeks before Visit 1 (with exception of sunscreen)
• Exclusion Criteria:
• • is currently pregnant or planning to conceive during the study period
• • is using topical or oral therapy or other treatment for melasma